ALKEM logo

Alkem Laboratories Limited Stock Price

NSEI:ALKEM Community·₹664.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

ALKEM Share Price Performance

₹5,555.50
73.60 (1.34%)
₹6,528.02
Fair Value
₹5,555.50
73.60 (1.34%)
16.9% undervalued intrinsic discount
₹6,684.00
Fair Value
Price ₹5,555.50
AnalystHighTarget ₹6,684.00
AnalystConsensusTarget ₹5,920.71
AnalystLowTarget ₹4,529.76

ALKEM Community Narratives

AnalystHighTarget·
Fair Value ₹6.53k 14.9% undervalued intrinsic discount

Rising Global Healthcare Demand And US CDMO Will Boost Generic Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹5.92k 6.2% undervalued intrinsic discount

Expanding Biosimilars And CDMO Will Open Global Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value ₹4.53k 22.6% overvalued intrinsic discount

Rising Cost Pressures And Regulatory Risks Will Undercut Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
₹5.92k
6.2% undervalued intrinsic discount
Revenue
9.79% p.a.
Profit Margin
14.16%
Future PE
38.81x
Price in 2028
₹8.45k
₹6.53k
14.9% undervalued intrinsic discount
Revenue
12.34% p.a.
Profit Margin
18.04%
Future PE
33.55x
Price in 2028
₹9.3k

Trending Discussion

Updated Narratives

ALKEM logo

ALKEM: Higher Profit Outlook Will Likely Fail To Offset Rising Risk

Fair Value: ₹4.53k 22.6% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ALKEM logo

ALKEM: Upcoming Product Launches And Board Review Will Influence Medium-Term Prospects

Fair Value: ₹5.92k 6.2% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ALKEM logo

Rising Global Healthcare Demand And US CDMO Will Boost Generic Markets

Fair Value: ₹6.53k 14.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record and pays a dividend.

1 Risk
3 Rewards

Alkem Laboratories Limited Key Details

₹138.9b

Revenue

₹52.2b

Cost of Revenue

₹86.7b

Gross Profit

₹63.1b

Other Expenses

₹23.6b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
197.47
62.44%
17.00%
14.2%
View Full Analysis

About ALKEM

Founded
1973
Employees
18785
CEO
Vikas Gupta
WebsiteView website
www.alkemlabs.com

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Recent ALKEM News & Updates

Recent updates

No updates